Cargando…
Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass
BACKGROUND: The current literature recognises that left ventricular hypertrophy makes a key contribution to the high rate of premature cardiovascular mortality in dialysis patients. Determining how we might intervene to ameliorate left ventricular hypertrophy in dialysis populations has become a res...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720185/ https://www.ncbi.nlm.nih.gov/pubmed/23855560 http://dx.doi.org/10.1186/1471-2369-14-149 |
_version_ | 1782277932308234240 |
---|---|
author | Dunlop, Joanna Leigh Vandal, Alain Charles de Zoysa, Janak Rashme Gabriel, Ruvin Sampath Haloob, Imad Adbi Hood, Christopher John Matheson, Philip James McGregor, David Owen Ross Rabindranath, Kannaiyan Samuel Semple, David John Marshall, Mark Roger |
author_facet | Dunlop, Joanna Leigh Vandal, Alain Charles de Zoysa, Janak Rashme Gabriel, Ruvin Sampath Haloob, Imad Adbi Hood, Christopher John Matheson, Philip James McGregor, David Owen Ross Rabindranath, Kannaiyan Samuel Semple, David John Marshall, Mark Roger |
author_sort | Dunlop, Joanna Leigh |
collection | PubMed |
description | BACKGROUND: The current literature recognises that left ventricular hypertrophy makes a key contribution to the high rate of premature cardiovascular mortality in dialysis patients. Determining how we might intervene to ameliorate left ventricular hypertrophy in dialysis populations has become a research priority. Reducing sodium exposure through lower dialysate sodium may be a promising intervention in this regard. However there is clinical equipoise around this intervention because the benefit has not yet been demonstrated in a robust prospective clinical trial, and several observational studies have suggested sodium lowering interventions may be deleterious in some dialysis patients. METHODS/DESIGN: The Sodium Lowering in Dialysate (SoLID) study is funded by the Health Research Council of New Zealand. It is a multi-centre, prospective, randomised, single-blind (outcomes assessor), controlled parallel assignment 3-year clinical trial. The SoLID study is designed to study what impact low dialysate sodium has upon cardiovascular risk in dialysis patients. The study intends to enrol 118 home hemodialysis patients from 6 sites in New Zealand over 24 months and follow up each participant over 12 months. Key exclusion criteria are: patients who dialyse more frequently than 3.5 times per week, pre-dialysis serum sodium of <135 mM, and maintenance hemodiafiltration. In addition, some medical conditions, treatments or participation in other dialysis trials, which contraindicate the SoLID study intervention or confound its effects, will be exclusion criteria. The intervention and control groups will be dialysed using dialysate sodium 135 mM and 140 mM respectively, for 12 months. The primary outcome measure is left ventricular mass index, as measured by cardiac magnetic resonance imaging, after 12 months of intervention. Eleven or more secondary outcomes will be studied in an attempt to better understand the physiologic and clinical mechanisms by which lower dialysate sodium alters the primary end point. DISCUSSION: The SoLID study is designed to clarify the effect of low dialysate sodium upon the cardiovascular outcomes of dialysis patients. The study results will provide much needed information about the efficacy of a cost effective, economically sustainable solution to a condition which is curtailing the lives of so many dialysis patients. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry number: ACTRN12611000975998 |
format | Online Article Text |
id | pubmed-3720185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37201852013-07-24 Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass Dunlop, Joanna Leigh Vandal, Alain Charles de Zoysa, Janak Rashme Gabriel, Ruvin Sampath Haloob, Imad Adbi Hood, Christopher John Matheson, Philip James McGregor, David Owen Ross Rabindranath, Kannaiyan Samuel Semple, David John Marshall, Mark Roger BMC Nephrol Study Protocol BACKGROUND: The current literature recognises that left ventricular hypertrophy makes a key contribution to the high rate of premature cardiovascular mortality in dialysis patients. Determining how we might intervene to ameliorate left ventricular hypertrophy in dialysis populations has become a research priority. Reducing sodium exposure through lower dialysate sodium may be a promising intervention in this regard. However there is clinical equipoise around this intervention because the benefit has not yet been demonstrated in a robust prospective clinical trial, and several observational studies have suggested sodium lowering interventions may be deleterious in some dialysis patients. METHODS/DESIGN: The Sodium Lowering in Dialysate (SoLID) study is funded by the Health Research Council of New Zealand. It is a multi-centre, prospective, randomised, single-blind (outcomes assessor), controlled parallel assignment 3-year clinical trial. The SoLID study is designed to study what impact low dialysate sodium has upon cardiovascular risk in dialysis patients. The study intends to enrol 118 home hemodialysis patients from 6 sites in New Zealand over 24 months and follow up each participant over 12 months. Key exclusion criteria are: patients who dialyse more frequently than 3.5 times per week, pre-dialysis serum sodium of <135 mM, and maintenance hemodiafiltration. In addition, some medical conditions, treatments or participation in other dialysis trials, which contraindicate the SoLID study intervention or confound its effects, will be exclusion criteria. The intervention and control groups will be dialysed using dialysate sodium 135 mM and 140 mM respectively, for 12 months. The primary outcome measure is left ventricular mass index, as measured by cardiac magnetic resonance imaging, after 12 months of intervention. Eleven or more secondary outcomes will be studied in an attempt to better understand the physiologic and clinical mechanisms by which lower dialysate sodium alters the primary end point. DISCUSSION: The SoLID study is designed to clarify the effect of low dialysate sodium upon the cardiovascular outcomes of dialysis patients. The study results will provide much needed information about the efficacy of a cost effective, economically sustainable solution to a condition which is curtailing the lives of so many dialysis patients. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry number: ACTRN12611000975998 BioMed Central 2013-07-15 /pmc/articles/PMC3720185/ /pubmed/23855560 http://dx.doi.org/10.1186/1471-2369-14-149 Text en Copyright © 2013 Dunlop et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Dunlop, Joanna Leigh Vandal, Alain Charles de Zoysa, Janak Rashme Gabriel, Ruvin Sampath Haloob, Imad Adbi Hood, Christopher John Matheson, Philip James McGregor, David Owen Ross Rabindranath, Kannaiyan Samuel Semple, David John Marshall, Mark Roger Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass |
title | Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass |
title_full | Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass |
title_fullStr | Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass |
title_full_unstemmed | Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass |
title_short | Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass |
title_sort | rationale and design of the sodium lowering in dialysate (solid) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720185/ https://www.ncbi.nlm.nih.gov/pubmed/23855560 http://dx.doi.org/10.1186/1471-2369-14-149 |
work_keys_str_mv | AT dunlopjoannaleigh rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT vandalalaincharles rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT dezoysajanakrashme rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT gabrielruvinsampath rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT haloobimadadbi rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT hoodchristopherjohn rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT mathesonphilipjames rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT mcgregordavidowenross rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT rabindranathkannaiyansamuel rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT sempledavidjohn rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass AT marshallmarkroger rationaleanddesignofthesodiumloweringindialysatesolidtrialarandomisedcontrolledtrialoflowversusstandarddialysatesodiumconcentrationduringhemodialysisforregressionofleftventricularmass |